BIOCON Results Analysis

Operating Revenue for Q2FY26 is Rs. 4,296 Cr., 19.64% Growth YoY, Total Income is Rs. 4,389 Cr., 21.13% Growth YoY, EBITDA is Rs. 835 Cr., 21.89% Growth YoY, EBITDA Margin is 19.45% improved by 36 Basis points YoY, PBT Rs. 171 Cr. 74.09% Growth YoY, PAT Rs. 133 Cr., 390% Growth YoY. Biosimilars and Generics businesses delivered double-digit Y-o-Y growth, CRDMO business performance in-line with plan. Over 40% YoY growth in EBITDA in Biosimilars. EBITDA Margin at 25%, a 400bps YoY expansion reflecting improved operating leverage. On QoQ basis Operating Revenue has 8.97% Growth, EBITDA is also grown by 9%, EBITDA Margins were flat, PBT has 76.8% Growth QoQ, PAT has 48.9% Growth QoQ. All the businesses are well poised to build on their momentum to deliver sustainable, long-term value for all stakeholders.